Medication Monitor



Generic Name (Trade Name—Company)
Notes
August 29, 2018

Loteprednol etabonate ophthalmic suspension

(Inveltys—Kala Pharmaceuticals)
First twice-daily ocular corticosteroid approved for postop pain and inflammation

Kala Pharmaceuticals announced FDA approval of loteprednol etabonate ophthalmic suspension 1% under the trade name Inveltys for the treatment of postoperative inflammation and pain following ocular surgery. It is the first twice-daily ocular corticosteroid approved for this indication.

In a news release, Kala stated that all other ocular steroids are approved for four-times-a-day dosing only, a dosing requirement that can lead to issues for both doctors and patients. Corticosteroids are the foundation of therapy for postocular surgery care, with the key goal of controlling inflammation and pain caused by surgical trauma to the eye.

In clinical trials, the most common adverse drug reactions were eye pain (1%) and posterior capsular opacification (1%). These reactions may have been the consequence of the surgical procedure.